Emmanuelle Porte

As a Corporate partner in the Bird & Bird Life Sciences team in Paris, I mainly advise innovative companies financed by venture capital, in particular biotech/medtech, digital health, and wellness companies.

I represent companies in the Life Sciences sector (biotech/medtech/healthtech), innovative technology companies and their executive, industrial or financial shareholders throughout their development: from incorporation, to venture capital and development capital fundraising operations, stock market financing, mergers and acquisitions and build-ups, as well as the structuring of joint ventures. I also represent French and foreign venture capital funds and corporate venture funds in the Life Sciences sector.

My goal is to create long-term relationships with my clients to assist them on their day-to-day business, but also on complex transactions, for their trade sale, their build up operations or for their IPO on Euronext or on other markets. I also represent French or foreign venture capital firms in connection with their investments in these life sciences companies.

I enjoy working with a genuine team of experts of the life sciences international team within Bird & Bird that can bring value to my clients, in particular in intellectual property, regulatory, IT, collaboration and licensing matters. I really feel that my corporate work for clients is enhanced by Bird & Bird's thorough knowledge of the life sciences industry in France and internationally.

For more than 10 years, I have been navigating the French life sciences ecosystem, with serial entrepreneurs, researchers, scientists, engineers and financiers, which is a fascinating world facing huge challenges for patients' health, including the revolution of artificial intelligence, data use and the digitalisation of health. I feel, in all humility, that I am contributing to this noteworthy and exciting cause: helping fund health research.

I am co-managing partner of the Bird & Bird offices in France since September 2021.

• I am proud to have advised several biotechnology and medical technology companies in their IPO on Euronext.
• Advised Implanet, a medical technology company listed on Euronext that specialises in spinal and knee implants, with its acquisition of Orthopaedic & Spine Development, which specialises in the design, manufacture and sale of implants for spinal surgery. The acquisition will make Implanet a key player in orthopaedic surgery.
• Advised Enterome, the French microbiome biopharma, on its €30 million Series E round with Symbiosis, Takeda, Nestlé Health Science, Health for Life Capital and its €40 million financing with European Investment Bank.
• Advising NovAliX, in connection with the takeover of part of the research and development activities and laboratories of Janssen France at the Val-de-Reuil site.
• Advising CorWave, a biotechnology company specialized in the research, development, manufacture and marketing of medical devices relating to innovative implantable blood pumps, on its Series C fund raising amounting 35 million euros, subscribed by its historic investors and new investors.
• Advising SparingVision, a biotechnology company focused on the discovery and development of innovative therapies for the treatment of inherited retinal diseases that cause blindness and in particular for Retinitis Pigmentosa, in the scope of its 44.5 M€ Series A2 fund raising subscribed by its historic investors (BPI, Foundation Fighting Blindness) and new investors (Jeito, Ysios, 4BIO and UPMC Enterprise) and then in its merger with GAMUT Therapeutics, a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa.